
Sign up to save your podcasts
Or


In July 2023, the US Food and Drug Administration (FDA) approved Opill, a daily progestin-only oral contraceptive for over-the-counter sale to people of all ages. Daniel Grossman, MD, discusses this and more with JAMA Associate Editor Melissa A. Simon, MD, MPH. Related Content:
By JAMA Network4.4
472472 ratings
In July 2023, the US Food and Drug Administration (FDA) approved Opill, a daily progestin-only oral contraceptive for over-the-counter sale to people of all ages. Daniel Grossman, MD, discusses this and more with JAMA Associate Editor Melissa A. Simon, MD, MPH. Related Content:

321 Listeners

549 Listeners

701 Listeners

163 Listeners

260 Listeners

906 Listeners

3,374 Listeners

38 Listeners

21 Listeners

16 Listeners

11 Listeners

8 Listeners

17 Listeners

19 Listeners

5 Listeners

6 Listeners

1,150 Listeners

31 Listeners

9 Listeners

94 Listeners

141 Listeners

14 Listeners

5 Listeners

518 Listeners

5 Listeners

367 Listeners

260 Listeners

437 Listeners

106 Listeners

18 Listeners

320 Listeners

2 Listeners

325 Listeners

270 Listeners